May 17, 2019
Camel-IDS appoints Thomas Ramdahl as Independent Director
Brussels (Belgium), 17 May 2019
The appointment follows the EUR 37m Series A round and supports the next growth stage
The Board now consists of Christin...
Read more
Read more
May 16, 2019
Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019
May 16, 2019 - Regulatory press release Press releases
Stockholm – May 16, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that a total of four...
Read more
Read more
May 15, 2019
Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting
May 15, 2019 - Regulatory press release Press releases
Stockholm – May 15, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from its P...
Read more
Read more
May 15, 2019
GenSight Biologics reports positive 96-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
15 May 2019
Press releases
Durable improvement in best-corrected visual acuity (BCVA), as GS010-treated eyes sustain +15.4 ETDRS letters equivalent impr...
Read more
Read more
May 14, 2019
Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update
May 14, 2019 at 4:15 PM EDT
Conference Call & Webcast Scheduled for Wednesday, May 15, at 8:30am Eastern Time
GAITHERSBURG, Md., May 14, 2019 (GLOBE NEWSWIRE) -...
Read more
Read more
May 10, 2019
MIPS – World’s First Safety Helmet With MIPS Brain Protection System Released
May 10, 2019
The Swedish brain protection brand, MIPS, announces Guardio as its first partner in the industrial safety helmet industry.
MIPS, the leading brain pr...
Read more
Read more
May 9, 2019
Pulmonx Closes $65 Million Financing and Adds Chief Financial Officer
Financing to Expand the U.S. Launch and Global Commercialization of the Zephyr Valve, a Less Invasive Treatment Option for Severe Emphysema/COPD
May 09, 2019 08:30 AM Eastern...
Read more
Read more
May 9, 2019
Targovax ASA: First quarter 2019 results
May 9, 2019
Press release - Regulatory
Oslo, Norway, 9 May 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activator...
Read more
Read more
May 9, 2019
Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Academy of Neurology Annual Meeting
~ Results Demonstrate Long-term Treatment with KEVEYIS is Efficacious and Provides Durable Reduction in Attack Frequency and Severity in Patients with PPP ~
DUBLIN, Irelan...
Read more
Read more
May 8, 2019
Altimmune to Announce First Quarter 2019 Financial Results on May 15
May 8, 2019 at 8:00 AM EDT
GAITHERSBURG, Md., May 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc.(Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announc...
Read more
Read more